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affects donor T cell expansion, activation and migration. We com-
pared lethally irradiated vs. non-irradiated Balb/c (H-2d) mice that
received allogeneic luciferase FVB/N T cells (H-2q). In vivo
bioluminescence imaging (BLI) visualized the kinetics of aGVHD
and guided more detailed analyses. Irradiated wild type Balb/c,
Balb/c Rag/ and Balb/c Rag/cchain/ aHCT recipients
displayed comparable kinetics of aGVHD initiation in lymphoid
organs until day 3 and started intestinal inﬁltration by day 4,
skin and liver inﬁltration by day 5-6. All mice succumbed to
lethal aGVHD within two weeks after aHCT. Non-irradiated
Balb/c wild type recipients did not develop aGVHD. BLI revealed
the process of graft rejection after initial signal increase over lymphoid
organs by day3. In contrast donor cells overcame host resistance in
non-irradiated Balb/c Rag/ and Balb/c Rag/cchain/ mice.
However, despite proliferation in lymphoid organs, inﬁltration of
aGVHD target tissues was delayed. Balb/c Rag/ displayed moder-
ate and Balb/c Rag/cchain/ mice even weaker intestinal inﬁl-
tration on day 6. FACS analysis revealed that donor T cell subsets
were less activated in non-irradiated as compared to irradiated hosts.
Non-irradiated Balb/c Rag/cchain/ mice succumbed to lethal
aGVHDwithin twomonths after aHCT. Balb/c Rag/mice did not
die from aGVHD suggesting that host NK cells controlled alloreac-
tive T cells. In summary host conditioning exacerbates aGVHD by
increased alloreactive T cell activation and recruitment to aGVHD
target tissues.
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EPIDERMAL DENDRITIC CELL DEPLETION WITH MYELOABLATIVE
CONDITIONING THAT DOES NOT RECOVER POST TRANSPLANT
Hofmeister, C.C.1, Peterson, A.1, Tara, K.2, Stiff, P.1, Curry, J.1,
Nickoloff, B.J.1 1. Loyola Cardinal Bernardin Cancer Center, Maywood,
IL; 2. Lake Erie College of Osteopathic Medicine, Bradenton, FL.
Introduction: Cutaneous graft-versus-host disease (GVHD) is
an antigen presenting cell mediated process which leads donor T
lymphocytes to presumably target keratinocyte progenitor cells at
the dermal-epidermal junction. In the absence of inﬂammation,
epidermal dendritic cells (a.k.a. Langerhans cells or LCs) can
self-renew for long periods of time without the requirement for a
bone-marrow derived blood-borne precursor. Murine models have
suggested that depletion of host LCs pretransplant prevents cuta-
neous GVHD. We sought to determine epidermal dendritic cell
density pre-transplant, post-transplant, and with the onset of acute
GVHD. Methods: We reviewed all skin biopsies performed on
2101 stem cell transplants patients at Loyola University Medical
Center from 1995-2005. From these parafﬁn-embedded blocks, 20
randomly selected acute GVHD biopsies, all 17 biopsies of non-
GVHD rashes in post allograft patients, and 12 normal skin biop-
sies from reduction mammoplasties were obtained. In addition as
part of a prospective trial, 14 patients underwent punch biopsies
from December 2004 to August 2005 of grossly normal skin before
and immediately following the completion of their conditioning
regimens. All biopsies were stained for CD1a (LC marker) and the
number of suprabasal stained cells per high power ﬁeld (HPF) were
counted by a dermatopathologist. Results: Total body irradiation
containing (TBI) conditioning regimens nearly completely elimi-
nated epidermal LCs by the day of transplant. In comparison to
normal skin (44 CD1a cells  4.7 [95% CI]), acute GVHD
lesions showed a depletion of epidermal LCs (3.7 CD1a cells 
3.2 [95% CI]), but so did biopsies obtained post allograft without
GVHD (6.5 CD1a cells  3.6 [95% CI]). Conclusions: My-
eloablative conditioning regimens deplete epidermal LCs and this
reduction may remain post engraftment. UV dermatitis, topical
steroids or tacrolimus, viral infections (HPV, HIV), and GVHD all
induce LC depletion. The mechanism for this depletion is un-
known but mediators such as TNF-
 and IL-1 have induced LC
migration in murine models (Roake JE, J Exp Med, 1995). Our data
suggest that pretransplant LC depletion in humans will not prevent
cutaneous GVHD. Future studies will need to be performed to
determine the origin of LCs in post allograft patients.
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HOST LANGERHANS CELLS (LCs) CAN BE THERAPEUTICALLY MANIP-
ULATED IN VIVO WITH IMIQUIMOD (TLR7 AGONIST) TO AUGMENT
DLI-MEDIATED GVH AND GVL REACTIVITY
Skarica, M., Radojcic, V., Luznik, L. Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins, Baltimore, MD.
We recently found in murine models that after MHC-matched
allografting, the residual host LCs, the major dendritic cells (DCs)
of the skin, survive in epidermis despite the presence of large
numbers of peripheral donor T cells in the graft and conversion to
the full donor DC chimerism in blood. This observation led us to
hypothesize that in vivo manipulation of residual host LCs, which
persist in complete donor chimeras after MHC-matched allograft-
ing, may have a central role in augmenting DLI-mediated alloim-
mune responses. We tested our hypothesis in two murine models
of MHC-matched allografting. To manipulate T cell-LC interac-
tion in vivo we used the Toll-like receptor 7 (TLR7) ligand imi-
quimod. Topical application of imiquimod is known to augment in
situ maturation of the LCs and enhance their emigration from the
skin to the skin-draining lymph nodes (LNs). We ﬁrst tracked the
in vivo fate of DLI-derived T cells after their administration to the
8-week-old B6.SJL3C3H.SW complete donor chimeras that
were pretreated with vehicle or imiquimod. As DLI, we used
puriﬁed donor T cells from the B6.PL-Thy1a mice that differ in the
expression of Thy 1.1 allele. In the imiquimod treated group, the
expansion of DLI-derived Thy 1.1 T cells in LNs and spleen was
signiﬁcantly better than that of the vehicle-treated group. This
augmented DLI-mediated GVH response was also reﬂected by a
higher number of DLI-derived CD8 INF- secreting T cells and
by an increase in donor-derived LC chimerism in the imiquimod-
treated group. Next, we tested the effect of imiquimod on the GVL
reactivity of DLI. Four-week-old C3H.SW3C57/BL6 chimeras
constructed after lethal conditioning were pretreated with imi-
quimod prior to DLI administration and lethal challenge with
C1498 leukemia cells. Chimeras that received imiquimod and DLI
had superior leukemia-free survival in comparison to animals that
received DLI plus vehicle (P  .01) or imiquimod alone (P  .02).
The superior leukemia-free survival in the group that received DLI
plus imiquimod correlated also with faster conversion to full donor
CD8 T cell chimerism in comparison to the DLI plus vehicle
group (P  .01). In both models, we have not observed any
signiﬁcant clinical signs of GVHD. These results indicate that
imiquimod, through its action on LCs, can be used to enhance the
DLI-mediated alloimmune responses including their GVL reac-
tivity without exacerbating GVHD.
147
SIGNIFICANT DECREASE IN CORD BLOOD (CB) VERSUS ADULT PE-
RIPHERAL BLOOD (APB) MONOCYTE (MO)–DERIVED DENDRITIC CELL
(DC) GENE AND PROTEIN EXPRESSION PATTERNS AND T CELL FUNC-
TIONAL ACTIVATION: INSIGHT INTO IMMATURITY OF CB CELLULAR
IMMUNITY
Jiang, H.1, Wade-Harris, C.1, Baxi, L.2, Cairo, M.S.1,3,4 1. Depart-
ment of Pediatrics, Columbia University, New York, NY; 2. Department
of Obstetrics & Gynecology, Columbia University, New York, NY; 3.
Department of Medicine, Columbia University, New York, NY; 4.
Department of Pathology, Columbia University, New York, NY.
It has been recognized that dysfunction of CB cellular immunity
is in part due to the immaturity of the CB cellular immune system
(Cairo, 1997). However, biological pathways and molecular mech-
anisms associated with the immaturity of CB cellular immunity are
still poorly understood. Recently we have utilized oligonucleotide
microarray to examine gene expression proﬁle of CB vs APB Mo
and have demonstrated signiﬁcant differential gene expression pat-
terns (Jiang/Cairo, 2004). In the current study, differential ex-
pressed genes and proteins were examined in Mo-derived CB vs
APB DC by means of oligonucleotide microarray and proteomics.
Brieﬂy, Mo were puriﬁed and cultured for 8 days with GM-CSF,
IL-4 and LPS. Oligonucleotide microarray was carried out (Af-
fymetrix). The proteomic study was conducted by liquid chroma-
tography (LC) and tandem mass spectrometry (MS/MS). We iden-
tiﬁed gene expression patterns that were signiﬁcantly lower in CB
Poster Session I
52
vs APB DC including surface molecules HLA-DQA1 (4F), HLA-
DRB3 (5F); cytokine/chemokine genes IL6 (2.9F), IL12B (3.5F),
CXCL10 (6.6F); immunoregulatory genes ISG20 (11F),
TNFSF10 (4.5F). The proteomic results indicated several zinc
ﬁnger proteins (292, 221) (2-5F) and interleukin-4 precursor (7.7F)
were expressed higher in APB vs CB (mDC). In contrast, cell cycle
regulators cyclin I (3F), Rb-like protein 2 (4.35 F) were signiﬁ-
cantly lower in APB vs CB DC. We then compared CB vs APB DC
antigen presentation activity to APB CD8 T cells by ELISPOT
assay for interferon-r (IFNr) production (BD Pharmingen).
Brieﬂy, CD8 T cells (MHC HLA A2) were incubated with CB or
APB DC that were loaded without or with inﬂuenza peptide onto
ELISPOT plate. Inﬂuenza peptide loaded CB mDC signiﬁcantly
reduced the ability to induce CD8 T cells to produce IFNr com-
pared with APB mDC (3.5F). We postulate that decreased expres-
sion of speciﬁc surface molecules and other genes and proteins
resulting in lower surface protein expression in CB DC may in part
be responsible for the lack of initiation of cell surface signaling
events to trigger CB-DC to induce activation of CD8 T cells.
Furthermore, these signiﬁcantly decreased expressed genes and
proteins in LPS-CB vs APB DC may also partially be responsible
for differential innate and adaptive immune function and proper-
ties of CB vs. APB.
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EX VIVO ACTIVATED AND TRANSDUCED HUMAN T CELLS GENERATE
LETHAL GVHD IN A MOUSE MODEL, AND ARE EFFICIENTLY ELIMI-
NATED IN VIVO WITH SUICIDE GENE THERAPY
Nervi, B.1, Rettig, M.P.1, Ritchey, J.K.1, Wang, H.L.1, Bauer, G.1,
Walker, J.1, Bonyhadi, M.L.2, Berenson, R.J.2, Herrbrich, P.E.1,
Hess, D.1, Nolta, J.A.1, DiPersio, J.F.1 1. Washington University
School of Medicine, St. Louis, MO; 2. Xcyte Therapies, Inc., Seattle,
WA.
No in vivo models exist to consistently examine the impact of
ex vivo manipulation of human T cells (huT) on T cell function.
NOD SCID2Mnull mice (2) were conditioned with 250 cGy
TBI on day 1 (n  34), or 300 cGy on day 0 (n  21). 107 naive
or CD3/28 bead activated (Xcyte™ Dynabeads) huT (Act)
were injected retro-orbitally (ro). Engraftment of huT was eval-
uated weekly by FACS and euthanasia was performed if mice
lost 	20% body weight. 2 mice receiving 250 or 300 cGy 
naive, or 300 cGy  Act developed 60%, 75%, and 100% lethal
GVHD respectively. The huT engraftment was 20  15%, 33 
21%, and 59  19% respectively. Inﬁltration of murine tissues
was greatest in mice receiving 300 cGy  Act huT (spleen, liver,
lung, kidney: 60%). Of interest, serum human IFN levels
increased over time in all mice who developed lethal GVHD
(P  .05). Importantly, histological examination of the target
tissues revealed changes consistent with human GVHD. We
developed a chimeric suicide gene consisting of human CD34
and full length HSV-tk and showed that the fusion protein
CD34-TK conferred ganciclovir (GCV) sensitivity and pro-
vided a surface marker for selection of transduced cells (Td). To
generate Td cells we used CD3/28 beads  IL-2, and after 2
days cells were incubated with 293 GPG-derived VSV-G
pseudotyped CD34-tk oncoretroviral supernatants for 6h at
37C. Td cells were then expanded for 2 more days and isolated
by MACS (Miltenyi Biotech) and puriﬁed to 	99% by CD34
(VarioMACS). To evaluate the Td GVHD potential, 2 mice
received 300 cGy and were injected with 107 Act (n  7) or Td
(n  4) huT. Both groups developed similar engraftment with
49  23% and 49  10% huT respectively (P  NS); had
important inﬁltration in target organs (55% in the liver), and
developed lethal GVHD. Subsequently, we evaluated the ability
of GCV (days 1-7) to prevent GVHD after infusion of Td. 2
mice (n  8) conditioned with 300 cGy were injected ro with
107 Td and 50% received GCV. We efﬁciently eliminated Td
huT with GCV (day 3 0.1  0.06; day 24 0.1  0.1 Td cells). In
summary, we developed a xenogeneic model of lethal GVHD
where naive, ex vivo activated, or Td selected CD34tk huT
injected ro into sublethally irradiated 2 mice engraft, expand in
vivo, inﬁltrate target tissues sharing the major characteristics of
human GvHD, and causing the death of mice. Interestingly, Td
T cells could be efﬁciently eliminated in vivo by treatment with
GCV, meaning we could potentially control human GVHD
with the suicide system.
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PERSISTENT MIXED CHIMERISM IN PLASMA CELLS FOLLOWING AL-
LOGENEIC STEM-CELL TRANSPLANTATION (SCT) IN PATIENTS WITH
ACUTE LEUKEMIA IS A SURROGATE MARKER FOR LEUKEMIA RELAPSE
Shimoni, A., Trakhtenbrot, L., Ishoev, G., Hardan, I., Shem-Tov, N.,
Rechavi, G., Amariglio, N., Nagler, A. Chaim Sheba Medical Center,
Tel-Hashomer, Israel.
Chimerism within cellular subsets following allogeneic SCT has
been studied extensively, yet there is only limited data on chimer-
ism kinetics within plasma cells (PC) and its prognostic signiﬁ-
cance. In this study we prospectively analyzed the relative ratios of
recipient and donor-derived PC in pts with acute leukemia at serial
time-points following SCT from a sex-mismatched donor in rela-
tion to SCT outcomes. Bone-marrow (BM) preparations were
evaluated by a Duet combined cytogenetic/morphologic analysis
system (Bioview LtD, Israel). The system scans BM preparations
and saves all cell coordinates. PC are detected and marked by their
morphology. The stain is then removed and FISH for  and Y
markers is applied to the same slide allowing differentiation of
recipient and donor PC by their gender. The study included 50 pts
following myeloablative (n  22) or reduced-intensity condition-
ing (n  28). Thirty-six pts (72%) had recipient PC detected early
after SCT, constituting 0.01-1.6% of BM cells. This was often
associated with low level recipient chimerism (1%) in lympho-
cytes. Early detection of recipient PC was not related to donor
type, conditioning regimen or acute GVHD, and had no prognos-
tic signiﬁcance. The median time to disappearance of recipient PC
was 12 months. In 16 of the 36 pts with recipient PC they persisted
beyond 6 months (and up to 	18 months), in 10 they disappeared
by this time period, 6 died before 6 months with recipient PC and
4 have insufﬁcient follow-up. Persistence of recipient PC beyond 6
months was not associated with mixed-chimerism in other subsets
at this stage. BM tests beyond 6 months are available in 30 pts of
all 50 pts. The outcome of 16 pts with recipient PC persisting
beyond 6 months was signiﬁcantly inferior to 14 pts with no
recipient PC at this stage; 8 patients in the ﬁrst group relapsed
compared to only 1 pt in the second. The 2-year DFS was 35%
(7-62), and 91% (74-100), respectively (P  .02). Donor derived
PC were detected during the course in 27 pts. The estimated
median time to ﬁrst detection of donor PC was 6 months (1-15).
Engraftment kinetics of donor PC had no relation to SCT out-
comes. In conclusion, recipient PC may persist for long durations
after allogeneic SCT and are relatively resistant to conditioning
and to allogeneic responses. Persistence of recipient PC beyond 6
months is a surrogate marker for ineffective GVL, even in pts with
GVHD, and is therefore associated with an increased risk for
leukemia relapse.
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INTENTIONAL INDUCTION OF IMMUNE-HEMATOPOIETIC MIXED CHI-
MERISM AS A PLATFORM FOR EARLY CELLULAR THERAPY IN PEDIAT-
RIC LEUKEMIA PATIENTS AFTER ALLOGENEIC TRANSPLANTATION:
ENHANCING GVL EFFECT WHILE AVOIDING GVHD
Diaz, M.A., Ramirez, M., Perez-Martinez, A., Gonzalez-Vicent, M.,
Garcia-Castro, J., Madero, L. Hematopoietic Stem Cell Transplantation
Unit, Hospital “Nin˜o Jesus,” Madrid, Spain.
To maximize graft-versus-leukemia (GvL) effect while mini-
mizing transplant-related morbidity and mortality, we designed
a study of allogeneic PBSC CD34 selected transplantation
followed by DLI. PBSC CD34 selection was performed by
CliniMACS device. Between June 2004 and July 2005, sixteen
consecutive patients (4 females and 12 males) aged between 1-12
years (median 6 years) diagnosed with AML 6, ALL 10 were
conditioned with ﬂudarabine 30 mg/m2/day  4 days and mel-
phalan 140 mg/m2/day  1 day. Status at transplantation was 1st
CR 10, 2nd CR 5 and 3rd CR 1. GvHD prophylaxis consisted of
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